Trial · NCT01270880
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT01270880, Phase 2, Completed, Barbara Ann Karmanos Cancer Institute; results first posted 2015-04-14
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy. Trials, record NCT01270880. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01270880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- NCT number
- NCT01270880
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction, enzyme-linked immunosorbent assay, RNA analysis, spectrophotometry, reverse transcriptase-polymerase chain reaction, gene expression analysis
- First posted
- 2011-01-05
- Last updated
- 2018-09-18
- Results first posted
- 2015-04-14
- Limitations and caveats
- Small sample size.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy | At 6 months | Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint. |
| Secondary | Percentage Change in PSA | From baseline to 12 weeks | Percentage change in PSA from baseline. |
| Secondary | Overall Safety and Tolerability of STA-9090 | Day 1, 8, and 15 of each course and at end of treatment | Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events |
| Secondary | OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy | From first dose to death or the date last known alive | Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method |
| Secondary | Association of PFS With PSA | At 6 months | Association of PFS with PSA using Cox PH regression model |
| Secondary | Potential Markers for Predicting Drug Response or Efficacy | At baseline, day 1 of course 3, and end of treatment | Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy | At 6 months | proportion with 6+ months PFS | NUMBER | |
| SECONDARY | Percentage Change in PSA | From baseline to 12 weeks | percentage change from baseline PSA | MEDIAN | |
| SECONDARY | Overall Safety and Tolerability of STA-9090 | Day 1, 8, and 15 of each course and at end of treatment | events of grade 3+ toxicity | NUMBER | |
| SECONDARY | OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy | From first dose to death or the date last known alive | months | MEDIAN | |
| SECONDARY | Association of PFS With PSA | At 6 months | Hazard Ratio | NUMBER | |
| SECONDARY | Potential Markers for Predicting Drug Response or Efficacy | At baseline, day 1 of course 3, and end of treatment | No data was collected for this outcome. |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy | Treatment (Enzyme Inhibitor Therapy) | 0.0 | 90% Confidence Interval 0.0 to 0.137 | proportion with 6+ months PFS | |
| Percentage Change in PSA | Treatment (Enzyme Inhibitor Therapy) | 78.65 | Full Range 34.11 to 353.45 | percentage change from baseline PSA | |
| Overall Safety and Tolerability of STA-9090 | Treatment (Enzyme Inhibitor Therapy) | 35 | events of grade 3+ toxicity | ||
| OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy | Treatment (Enzyme Inhibitor Therapy) | 12.5 | 90% Confidence Interval 1.5 to 17.7 | months | |
| Association of PFS With PSA | Treatment (Enzyme Inhibitor Therapy) | 1.000 | 95% Confidence Interval 0.999 to 1.001 | Hazard Ratio |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Enzyme Inhibitor Therapy) | 18 | |
| Overall Study | COMPLETED | Treatment (Enzyme Inhibitor Therapy) | 17 | |
| Overall Study | NOT COMPLETED | Treatment (Enzyme Inhibitor Therapy) | 1 |
Source ClinicalTrials.gov
Adverse events56
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alkaline phosphatase increased | Investigations | Treatment (Enzyme Inhibitor Therapy) | 6 | 18 | 6 |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Enzyme Inhibitor Therapy) | 5 | 18 | 5 |
| other | Aspartate aminotransferase increase | Investigations | Treatment (Enzyme Inhibitor Therapy) | 6 | 18 | 6 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Enzyme Inhibitor Therapy) | 10 | 18 | 10 |
| other | Fatigue | General disorders | Treatment (Enzyme Inhibitor Therapy) | 7 | 18 | 7 |
| other | Hematuria | Renal and urinary disorders | Treatment (Enzyme Inhibitor Therapy) | 4 | 18 | 4 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Enzyme Inhibitor Therapy) | 8 | 18 | 8 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (Enzyme Inhibitor Therapy) | 7 | 18 | 7 |
| other | Lymphocyte count decreased | Investigations | Treatment (Enzyme Inhibitor Therapy) | 7 | 18 | 7 |
| other | Nausea | Gastrointestinal disorders | Treatment (Enzyme Inhibitor Therapy) | 2 | 18 | 2 |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Enzyme Inhibitor Therapy) | ||
| Total, other adverse events | Treatment (Enzyme Inhibitor Therapy) | 17 | 18 |
| Total, serious adverse events | Treatment (Enzyme Inhibitor Therapy) | 10 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01270880
GET https://conductscience.org/api/trials/v1/NCT01270880/events?page=2